Predicted Trait | |
Reported Trait | Prostate-specific antigen (PSA) levels |
Mapped Trait(s) | prostate specific antigen amount (OBA_2050200) |
Additional Trait Information | log(PSA) in men without prostate cancer |
Score Construction | |
PGS Name | PSA_PGS_128 |
Development Method | |
Name | Clumping and Thresholding (C+T) |
Parameters | Clumping: p-value<5E-08 and LD r2<0.01 within 10Mb in 1000G EUR (additional step: check for LD r2<0.05 in 1000G ALL) |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 128 |
Effect Weight Type | NR |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000412 |
Citation (link to publication) | Kachuri L et al. Nat Med (2023) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 89.6% African: 3.7% East Asian: 3.5% Hispanic or Latin American: 3.2% 95,768 individuals (100%) |
PGS Evaluation |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
— | 85,824 individuals, 100.0 % Male samples |
European | BioVU, GERA, MDC, PLCO, UKB |
— | 3,509 individuals, 100.0 % Male samples |
African American or Afro-Caribbean | BioVU, GERA, PLCO |
— | 3,337 individuals, 100.0 % Male samples |
East Asian | GERA, PLCO |
— | 3,098 individuals, 100.0 % Male samples |
Hispanic or Latin American | GERA, PLCO |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM016240 | PSS010066| European Ancestry| 5,725 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.169 | — | Partial R2 (%, variation explained by the PGS only): 7.33 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016241 | PSS010073| Multi-ancestry (including European)| 25,917 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.207 | — | Partial R2 (%, variation explained by the PGS only): 8.0 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016242 | PSS010072| European Ancestry| 22,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.213 | — | Partial R2 (%, variation explained by the PGS only): 8.78 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016243 | PSS010070| African Ancestry| 2,936 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.154 | — | Partial R2 (%, variation explained by the PGS only): 3.36 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016244 | PSS010068| African Ancestry| 1,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.163 | — | Partial R2 (%, variation explained by the PGS only): 3.45 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016245 | PSS010069| African Ancestry| 1,763 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.146 | — | Partial R2 (%, variation explained by the PGS only): 3.32 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016246 | PSS010071| East Asian Ancestry| 257 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.136 | — | Partial R2 (%, variation explained by the PGS only): 2.45 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016239 | PSS010067| Multi-ancestry (including European)| 5,883 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.168 | — | Partial R2 (%, variation explained by the PGS only): 7.16 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS010066 | Baseline/pre-randomization PSA in men without prostate cancer | — | 5,725 individuals, 100.0 % Male samples |
— | European (Predominantly European) |
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.998; mean EUR = 0.991 | PCPT | Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL |
PSS010067 | Baseline/pre-randomization PSA in men without prostate cancer | — | 5,883 individuals, 100.0 % Male samples |
— | European, Not reported | Multi-ancestry pooled sample | PCPT | Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL |
PSS010068 | Baseline/pre-randomization PSA in men without prostate cancer | — | 1,173 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (Predominantly West African) |
West African (AFR) ancestry cluster based on SNPWEIGHTS score >=0.80; median AFR = 0.855; mean AFR = 0.861 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010069 | Baseline/pre-randomization PSA in men without prostate cancer | — | 1,763 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (West African admixed) |
0.20 < West African (AFR) ancestry score <0.80 based on SNPWEIGHTS; median AFR = 0.673; mean AFR = 0.602 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010070 | Baseline/pre-randomization PSA in men without prostate cancer | — | 2,936 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (West African admixed) |
West African (AFR) ancestry score >0.20 based on SNPWEIGHTS; median AFR = 0.765; mean AFR = 0.705 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010071 | Baseline/pre-randomization PSA in men without prostate cancer | — | 257 individuals, 100.0 % Male samples |
— | East Asian (Predominantly East Asian) |
East Asian (EAS) ancestry cluster based on SNPWEIGHTS score >=0.80; median EAS = 0.978; mean EAS = 0.972 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010072 | Baseline/pre-randomization PSA in men without prostate cancer | — | 22,173 individuals, 100.0 % Male samples |
— | European (Predominantly European) |
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.995; mean EUR = 0.986 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010073 | Baseline/pre-randomization PSA in men without prostate cancer | — | 25,917 individuals, 100.0 % Male samples |
— | European, African American or Afro-Caribbean | Multi-ancestry pooled sample | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |